GAD-7 Generalized Anxiety Disorder 7-Item Scale
This tool implements the standard 7-item Generalized Anxiety Disorder scale (GAD-7), a widely validated brief screening instrument for anxiety symptom severity originally published by Spitzer, Kroenke, Williams, and colleagues in 2006 (Archives of Internal Medicine 166:1092-1097) with development support from a Pfizer Inc. grant. The GAD-7 assesses the frequency of seven core anxiety-related symptoms over the past two weeks using a common four-point response scale (0 = Not at all through 3 = Nearly every day). No items are reverse-keyed; all seven items are summed directly to produce a total score ranging from 0 to 21, with higher values indicating greater self-reported anxiety symptom burden. The result is classified into four descriptive severity tiers: Minimal (0-4), Mild (5-9), Moderate (10-14), and Severe (15-21). The widely cited screening cutoff of ≥10 points corresponds, in the original primary care validation sample, to a documented sensitivity of 89% and specificity of 82% for generalized anxiety disorder as confirmed by structured diagnostic interview.
GAD-7 Assessment — Past Two Weeks
Symptom absent during the past two weeks
Present on some days but less than half the time
Present on a majority of days in the two-week window
Present on almost all or all days
Symptom absent during the past two weeks
Present on some days but less than half the time
Present on a majority of days in the two-week window
Present on almost all or all days
Symptom absent during the past two weeks
Present on some days but less than half the time
Present on a majority of days in the two-week window
Present on almost all or all days
Symptom absent during the past two weeks
Present on some days but less than half the time
Present on a majority of days in the two-week window
Present on almost all or all days
Symptom absent during the past two weeks
Present on some days but less than half the time
Present on a majority of days in the two-week window
Present on almost all or all days
Symptom absent during the past two weeks
Present on some days but less than half the time
Present on a majority of days in the two-week window
Present on almost all or all days
Symptom absent during the past two weeks
Present on some days but less than half the time
Present on a majority of days in the two-week window
Present on almost all or all days
GAD-7 Instrument: Scoring, Severity Tiers, and Psychometric Validation
Item Content and Standard Response Anchors
The GAD-7 contains seven items developed through iterative refinement from the longer Patient Health Questionnaire anxiety screening pool, designed to reflect the core symptom domains of generalized anxiety disorder as conceptualized in contemporary diagnostic frameworks. Specifically, the seven items sample: (Q1) subjective feelings of nervousness, anxious tension, and feeling "on edge"; (Q2) perceived inability to stop or control worry processes; (Q3) excessive worry spanning multiple different life domains; (Q4) difficulty relaxing and unwinding; (Q5) motor restlessness and psychomotor agitation; (Q6) irritability and lowered frustration tolerance; and (Q7) anticipatory fear and catastrophic apprehension. All items share a common two-week retrospective recall window and a common four-point frequency response scale with anchors 0 = Not at all, 1 = Several days, 2 = More than half the days, and 3 = Nearly every day. Critically, and in contrast to instruments such as the Perceived Stress Scale, no GAD-7 items are reverse-keyed; all seven items are scored in the same forward direction such that higher response values uniformly correspond to greater symptom frequency or severity.
Scoring Algorithm and Severity Thresholds
Because all GAD-7 items are scored directly and no reverse transformations are required, the scoring algorithm is exceptionally straightforward. Formally, for each of the seven items i with raw response ri ∈ {0, 1, 2, 3}, the scored contribution si equals ri. The total GAD-7 score is the arithmetic sum across all seven items: Total = Σ si for i = 1 … 7. Since each item contributes between 0 and 3 points, the closed theoretical range of the total score is [0, 21], with a population midpoint of 10.5 under a uniform distribution and an empirical community sample mean typically reported between approximately 4 and 6. The standard four-tier interpretive scheme, as recommended by the original developers and widely adopted in clinical practice and research literature, partitions the 0-21 range as follows: (1) Minimal anxiety symptom severity, scores 0 through 4; (2) Mild anxiety symptom severity, scores 5 through 9; (3) Moderate anxiety symptom severity, scores 10 through 14; and (4) Severe anxiety symptom severity, scores 15 through 21. These severity tiers are descriptive reference labels intended to support clinical decision-making and are not themselves diagnostic thresholds.
The ≥10 Cutoff: Documented Sensitivity of 89% and Specificity of 82%
The most extensively studied GAD-7 screening threshold is the cutoff score of 10 or greater, which the original developers recommended as the optimal balance point for identifying probable cases of generalized anxiety disorder in primary care and general medical settings. In the 2006 Spitzer et al. validation study published in Archives of Internal Medicine, which enrolled 2,743 adult primary care patients across 15 primary care clinics in the United States and used the structured Mini International Neuropsychiatric Interview (MINI) as the independent diagnostic reference standard, a GAD-7 score of ≥10 demonstrated a sensitivity of 89% — meaning that among participants who met formal diagnostic criteria for generalized anxiety disorder by structured interview, 89% correctly scored at or above 10 on the GAD-7 — and a specificity of 82% — meaning that among participants who did not meet diagnostic criteria for generalized anxiety disorder, 82% correctly scored below 10. The study further demonstrated that the GAD-7 also performs reasonably well as a general anxiety-spectrum screener beyond generalized anxiety disorder alone, with acceptable operating characteristics for panic disorder, social anxiety disorder, and post-traumatic stress disorder in the same validation sample, though the ≥10 cutoff was calibrated and optimized specifically for generalized anxiety disorder. As with all psychometric screening instruments, these sensitivity and specificity values are population-level descriptors derived from the specific validation sample and may vary in different demographic subgroups, comorbid populations, or care settings. They are presented here as documented published reference values for informational purposes only.
Public Domain Status and Pfizer Grant Acknowledgement
The GAD-7 is one component of the broader Patient Health Questionnaire (PHQ) suite of instruments, which includes the PHQ-9 depression severity module, the PHQ-15 somatic symptom module, and the original full-length PHQ diagnostic algorithm. Development of the PHQ suite, including the GAD-7 anxiety module, was supported by a grant from Pfizer Inc. to the principal investigators (Drs. Robert L. Spitzer, Kurt Kroenke, and Janet B. W. Williams). Following the standard practice established for the PHQ-9, the GAD-7 is explicitly made available to the public without cost by the developers and Pfizer Inc. No written permission, license, royalty, or fee is required to reproduce, administer, translate, adapt, or use the GAD-7 for any lawful purpose, including clinical practice, research, education, commercial software, mobile health applications, web-based screening platforms, and electronic health record integration. Consistent with standard academic convention, users of the instrument are requested to cite the original 2006 Spitzer et al. publication in Archives of Internal Medicine when reporting GAD-7 results in formal written, research, or regulatory contexts, and to avoid labeling substantially modified versions of the instrument as the GAD-7.
| GAD-7 Score Range | Severity Tier | Interpretive Reference |
|---|---|---|
| 0 – 4 | Minimal Anxiety | Few or no anxiety symptoms endorsed in the past two weeks; symptom burden at a level commonly observed in general community samples. |
| 5 – 9 | Mild Anxiety | Mild level of anxiety symptoms present on several days; may reflect transient situational stress or subclinical symptom burden; standard recommendation includes monitoring and supportive strategies. |
| 10 – 14 | Moderate Anxiety | Moderate symptom frequency often exceeding half the days; corresponds to the ≥10 screening cutoff with published sensitivity 89% / specificity 82% for generalized anxiety disorder; generally warrants further clinical evaluation per standard guidance. |
| 15 – 21 | Severe Anxiety | High frequency and intensity of anxiety symptoms across multiple domains, often present nearly every day; typically associated with meaningful functional impairment; strongly indicates that formal evaluation by a qualified mental health professional is warranted. |
Data Source and References
- [1] Spitzer RL, Kroenke K, Williams JBW, Löwe B (2006). A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7. Archives of Internal Medicine, 166(10):1092-1097. doi.org — Original development and primary care validation study; Pfizer Inc. grant support acknowledged; ≥10 cutoff sensitivity 89% / specificity 82% reported.
- [2] Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Löwe B (2010). Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Annals of Internal Medicine. — Cross-validation and extended assessment of GAD-7 diagnostic performance across multiple anxiety-spectrum conditions in primary care populations.
- [3] Pfizer Inc. / Patient Health Questionnaire public-use statement. — GAD-7 and PHQ-9 are officially designated publicly available instruments free for use at no cost; no permission, license, or fee required for clinical, research, educational, or commercial applications including software implementation.
Frequently Asked Questions
-
No. The GAD-7 (Generalized Anxiety Disorder 7-item scale) is a validated psychometric screening instrument designed to identify individuals who may warrant further clinical evaluation for generalized anxiety disorder and potentially other anxiety-spectrum conditions. It is not a diagnostic tool and does not, by itself, establish the presence of generalized anxiety disorder, panic disorder, social anxiety disorder, specific phobias, obsessive-compulsive disorder, post-traumatic stress disorder, or any other psychiatric diagnosis. An elevated GAD-7 score indicates a higher level of self-reported anxiety symptoms over the preceding two weeks and, per the developers' guidance, may be used to support a decision to proceed to formal diagnostic interview or referral, but a GAD-7 score alone is never sufficient for any clinical diagnosis.
-
The GAD-7 consists of seven items, all of which are scored in the same forward direction — no items are reverse-keyed. Each item uses a common four-point frequency response scale anchored to the past two weeks: 0 = Not at all, 1 = Several days, 2 = More than half the days, and 3 = Nearly every day. The total GAD-7 score is the simple arithmetic sum of the seven item responses, yielding a closed theoretical range of 0 to 21. Each item thus contributes equally (0 to 3 points) to the total score, with higher values uniformly indicating a greater frequency or severity of self-reported anxiety-related symptoms. This straightforward unidirectional scoring is one of the design features that makes the GAD-7 practical for rapid administration in primary care and community screening settings.
-
The GAD-7 cutoff score of 10 or greater is the most widely recommended threshold for identifying probable cases of generalized anxiety disorder that warrant further clinical evaluation. In the original 2006 validation study by Spitzer and colleagues, which was conducted in a large primary care sample with structured clinical interview as the reference standard, a cutoff of ≥10 demonstrated a sensitivity of 89% (meaning 89% of individuals confirmed to have generalized anxiety disorder by structured interview scored 10 or above on the GAD-7) and a specificity of 82% (meaning 82% of individuals who did not meet diagnostic criteria for generalized anxiety disorder scored below 10). These performance statistics are population-level values derived from the validation study sample; individual test performance may vary in different settings, demographic subgroups, or comorbid populations. The ≥10 cutoff represents a descriptive reference threshold, not a definitive diagnostic boundary.
-
Yes. The GAD-7, together with the related PHQ-9 depression module and the Patient Health Questionnaire suite of instruments, is explicitly placed in the public domain and made available without cost by the developers and the original sponsor (Pfizer Inc.). Per the developers' official public-use statement, no written permission, license, or fee is required to reproduce, administer, translate, adapt, or use the GAD-7 for clinical, research, educational, or commercial purposes, including incorporation into software, electronic health record systems, mobile applications, and web-based screening tools. The only customary expectation, consistent with standard academic practice, is that users of the instrument appropriately cite the original 2006 Spitzer et al. publication in Archives of Internal Medicine when reporting results in formal written or research contexts, and that any modifications to item wording or response anchors that substantially alter the construct being measured are no longer labeled as the GAD-7.